PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/58616

Please be advised that this information was generated on 2019-08-02 and may be subject to change.
Effectiveness and efficiency of guideline dissemination and implementation strategies

JM Grimshaw,1* RE Thomas,1 G MacLennan,1 C Fraser,1 CR Ramsay,1 L Vale,1,2 P Whitty,3 MP Eccles,4 L Matowe,1† L Shirran,1 M Wensing,5 R Dijkstra5 and C Donaldson6‡

1 Health Services Research Unit, University of Aberdeen, UK
2 Health Economics Research Unit, University of Aberdeen, UK
3 Department of Epidemiology and Public Health, University of Newcastle upon Tyne, UK
4 Centre for Health Services Research, University of Newcastle upon Tyne, UK
5 Centre for Quality of Care Research, University of Nijmegen, The Netherlands
6 Department of Community Health Sciences, University of Calgary, Canada

* Corresponding author. Current affiliation: Clinical Epidemiology Programme, Ottawa Health Research Institute and Center for Best Practices, Institute of Population Health, University of Ottawa, Canada
† Current affiliation: Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Kuwait
‡ Current affiliation: Centre for Health Services Research, University of Newcastle upon Tyne, UK

Executive summary

Health Technology Assessment 2004; Vol. 8: No. 6
Executive summary: Effectiveness and efficiency of guideline dissemination and implementation strategies

Background
Clinical practice guidelines are an increasingly common element of clinical care throughout the world. Such guidelines have the potential to improve the care received by patients by promoting interventions of proven benefit and discouraging ineffective interventions. However, the development and introduction of guidelines are not without costs. In some circumstances, the costs of development and introduction are likely to outweigh their potential benefits. In other circumstances, it may be more efficient to adopt less costly but less effective dissemination and implementation strategies. Local healthcare organisations have relatively few resources for clinical effectiveness activities and policy makers need to consider how best to use these to maximise benefits.

Objectives
The aims of the study were:

- to undertake a systematic review of the effectiveness and costs of different guideline development, dissemination and implementation strategies
- to estimate the resource implications of different development, dissemination and implementation strategies
- to develop a framework for deciding when it is efficient to develop and introduce clinical guidelines based upon the potential costs and benefits of the targeted clinical activity and the effectiveness and costs of guideline development and introduction.

Methods
Systematic review of the effectiveness and efficiency of guideline dissemination and implementation strategies

Data sources
MEDLINE (1966–1998), Healthstar (1975–1998), Cochrane Controlled Trial Register (4th edition 1998), EMBASE (1980–1998), SIGLE (1980–1988) and the specialised register of the Cochrane Effective Practice and Organisation of Care (EPOC) group were searched using a gold standard search strategy developed from handsearches of key journals. The search strategy was 93% sensitive and 18% specific.

Study selection (inclusion criteria)
- Types of study design: randomised controlled trials, controlled clinical trials, controlled before and after studies and interrupted time series
- types of participant: medically qualified healthcare professionals
- types of intervention: guideline dissemination and implementation strategies
- types of outcome: objective measures of provider behaviour and/or patient outcome.

Data extraction (and assessment of validity)
Two reviewers independently abstracted data on the methodological quality of the studies (using the Cochrane EPOC group’s methodological quality criteria), characteristics of study setting, participants, targeted behaviours and characteristics of interventions. Studies reporting economic evaluations and cost analyses were further assessed against the British Medical journal guidelines for reviewers of economic evaluations.

Data synthesis
Single estimates of dichotomous process variables (e.g. proportion of patients receiving appropriate treatment) were derived for each study comparison based upon the primary end-point (as defined by the authors of the study) or the median measure across several reported end-points. An attempt was made to reanalyse studies with common methodological weaknesses. Separate analyses were undertaken for comparisons of single interventions against ‘no-intervention’ controls, single interventions against controls receiving interventions, multifaceted interventions against ‘no-intervention’ controls and multifaceted interventions against controls receiving interventions. The study also explored whether the effects of multifaceted interventions increased with the number of intervention components. For each intervention, the number of comparisons showing a positive direction of effect, the
median effect size across all comparisons, the median effect size across comparisons without unit of analysis errors, and the number of comparisons showing statistically significant effects were reported. A planned meta-regression analysis could not be undertaken owing to the large number of different combinations of multifaceted interventions.

**Survey of estimating the feasibility and likely resource requirements of guideline dissemination and implementation strategies in UK settings**

Telephone interviews were conducted with key informants from primary and secondary care.

**Results (research findings)**

**Systematic review of the effectiveness and efficiency of guideline dissemination and implementation strategies**

In total, 235 studies reporting 309 comparisons met the inclusion criteria. The overall quality of the studies was poor. Seventy-three per cent of comparisons evaluated multifaceted interventions, although the maximum number of replications of a specific multifaceted intervention was 11 comparisons. Overall, the majority of comparisons reporting dichotomous process data (86.6%) observed improvements in care; however, there was considerable variation in the observed effects both within and across interventions. Commonly evaluated single interventions were reminders (38 comparisons), dissemination of educational materials (18 comparisons) and audit and feedback (12 comparisons). There were 23 comparisons of multifaceted interventions involving educational outreach. The majority of interventions observed modest to moderate improvements in care. For example, the median absolute improvement in performance across interventions was 14.1% in 14 cluster randomised comparisons of reminders, 8.1% in four cluster randomised comparisons of dissemination of educational materials, 7.0% in five cluster randomised comparisons of audit and feedback and 6.0% in 13 cluster randomised comparisons of multifaceted interventions involving educational outreach. No relationship was found between the number of component interventions and the effects of multifaceted interventions.

Only 29.4% of comparisons reported any economic data. Eleven reported cost-effectiveness analyses, 38 reported cost consequence analyses (where differences in cost were set against differences in several measures of effectiveness) and 14 reported cost analyses (where some aspect of cost was reported but not related to benefits). The majority of studies only reported costs of treatment; only 25 studies reported data on the costs of guideline development or guideline dissemination and implementation. The majority of studies used process measures for their primary end-point, despite the fact that only three guidelines were explicitly evidence based (and may not have been efficient). Overall, the methods of the economic evaluations and cost analyses were poor. The viewpoint adopted in economic evaluations was only stated in ten studies. The methods to estimate costs were comprehensive in about half of the studies, and few studies reported details of resource use. Owing to the poor quality of reporting of the economic evaluation, data on resource use and cost of guideline development, dissemination and implementation were not available for most of the studies; only four studies provided sufficiently robust data for abstraction.

**Survey of estimating the feasibility and likely resource requirements of guideline dissemination and implementation strategies in UK settings**

Respondents rarely identified existing budgets to support guideline dissemination and implementation strategies and made frequent comments about using ‘soft money’ or resources for specific initiatives to support such activities. In general, the respondents thought that only dissemination of educational materials and short (lunchtime) educational meetings were generally feasible within current resources.

**Conclusions: implications for healthcare and recommendations for research**

There is an imperfect evidence base to support decisions about which guideline dissemination and implementation strategies are likely to be efficient under different circumstances. Decision makers need to use considerable judgement about how best to use the limited resources they have for clinical governance and related activities to maximise population benefits. They need to consider the potential clinical areas for clinical effectiveness activities, the likely benefits and costs required to introduce guidelines and...
the likely benefits and costs as a result of any changes in provider behaviour. Further research is required to: develop and validate a coherent theoretical framework of health professional and organisational behaviour and behaviour change to inform better the choice of interventions in research and service settings, and to estimate the efficiency of dissemination and implementation strategies in the presence of different barriers and effect modifiers.

**Publication**

How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:

<table>
<thead>
<tr>
<th>HTA Despatch</th>
<th>Email: <a href="mailto:orders@hta.ac.uk">orders@hta.ac.uk</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>c/o Direct Mail Works Ltd</td>
<td>Tel: 02392 492 000</td>
</tr>
<tr>
<td>4 Oakwood Business Centre</td>
<td>Fax: 02392 478 555</td>
</tr>
<tr>
<td>Downley, HAVANT PO9 2NP, UK</td>
<td>Fax from outside the UK: +44 2392 478 555</td>
</tr>
</tbody>
</table>

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.
The NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.

Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.

The research reported in this monograph was identified as a priority by the HTA Programme’s Methodology Panel and was funded as project number 94/08/29.

The views expressed in this publication are those of the authors and not necessarily those of the Methodology Programme, HTA Programme or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

Methodology Programme Director: Professor Richard Lilford
HTA Programme Director: Professor Tom Walley
Series Editors: Dr Ken Stein, Professor John Gabbay, Dr Ruairidh Milne and Dr Rob Riemisma
Managing Editors: Sally Bailey and Caroline Ciupek

The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report. They would like to thank the referees for their constructive comments on the draft document.